Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05678218` - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Active, not recruiting	`NCT03781934` - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations	Phase 1/Phase 2
Completed	`NCT01938729` - Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma	Phase 1
Completed	`NCT03230318` - Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma	Phase 2
Recruiting	`NCT06239532` - HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma	Phase 2
Not yet recruiting	`NCT05535647` - Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma	Phase 2
Not yet recruiting	`NCT05009953` - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT02254681` - Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC	Phase 2
Active, not recruiting	`NCT01954745` - A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy	Phase 2
Completed	`NCT01347333` - Stereotactic Body Radiotherapy for Liver Tumors	N/A
Active, not recruiting	`NCT04526106` - REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05285358` - Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases	Phase 1
Completed	`NCT03320980` - RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma	N/A
Withdrawn	`NCT05019677` - GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC	Phase 2
Withdrawn	`NCT03801499` - Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma	Phase 2
Completed	`NCT05489692` - HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Recruiting	`NCT06101277` - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)	N/A
Active, not recruiting	`NCT01917370` - VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway	N/A
Withdrawn	`NCT01775280` - Response of Hepatic Tumors to Radioembolization	Phase 2
Not yet recruiting	`NCT05342194` - Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study	Phase 3

NCT number	NCT05672537
Study type	Interventional
Source	Tianjin Medical University Cancer Institute and Hospital
Contact
Status	Recruiting
Phase	Phase 2
Start date	January 20, 2023
Completion date	December 31, 2025

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms